Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/ Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience
Por:
Rodriguez-Otero P, Sirvent M, González-Rodríguez AP, Lavilla E, de Coca AG, Arguiñano JM, Martí JM, Cabañas V, Motlló C, de Cabo E, Encinas C, Murillo I, Hernández-Rivas JÁ, Pérez-Persona E, Casado F, Sampol A, García R, Blanchard MJ, Anguita M, Lafuente AP, Iñigo B, López A, Ribas P, Arnao M, Maldonado R, Bladé J, Mateos MV, Lahuerta JJ and San Miguel JF
Publicada:
1 jun 2021
Ahead of Print:
1 jun 2021
Resumen:
Treatment of relapsed/refractory multiple myeloma (RRMM) is highly challenging. We analyzed the efficacy and safety of pomalidomide, cyclophosphamide, and dexamethasone (PomCiDex) in a real-world RRMM population. Median progression-free and overall survival were 7.6 and 12.6 months, respectively, which compares favorably with other triplets in the same setting. PomCiDex remains a manageable, cost-effective, and all-oral triplet combination for RRMM.
Introduction: Treatment of relapsed/refractory multiple myeloma (RRMM) is highly challenging, especially for patients with disease refractory to initial therapy, and in particular for disease developing refractoriness to lenalidomide. Indeed, with currently approved treatments, median progression-free survival (PFS) in the lenalidomide-refractory setting is less than 10 months, reflecting the difficulty in treating this patient population. Pomalidomide is a second-generation immunomodulatory drug that has shown activity in lenalidomide-refractory disease in the setting of different combinations. Patients and Methods: A real-world study was conducted by the Spanish Myeloma group in a cohort of patients with RRMM treated with pomalidomide, cyclophosphamide, and dexamethasone (PomCiDex). One hundred patients were treated with a median of 3 prior lines of therapy. Results: Overall response rate was 39%, with a clinical benefit rate of 93%. Median PFS was 7.6 months; median overall survival (OS) was 12.6 months. Median PFS and OS survival were consistent across the different subgroups analyzed. Prolonged PFS and OS were found in patients with responsive disease. Conclusion: Our results compared favorably with those obtained with different pomalidomide-based combinations in a similar patient population. PomCiDex remains a manageable, cost-effective, and all-oral triplet combination for RRMM patients. (C) 2021 Published by Elsevier Inc.
Filiaciones:
Rodriguez-Otero P:
Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain
Sirvent M:
Department of Hematology, Hospital Donostia, San Sebastian, Spain
González-Rodríguez AP:
Department of Hematology, Hospital Universitario Central de Asturias, Oviedo, Spain
Lavilla E:
Department of Hematology, Hospital Lucus Augusti, Lugo, Spain
de Coca AG:
Department of Hematology, Hospital Clínico Universitario de Valladolid, Valladolid, Spain
Arguiñano JM:
Department of Hematology, Complejo Hospitalario de Navarra, Pamplona, Spain
Martí JM:
Department of Hematology, Hospital Universitari Mutua Terrassa, Terrassa, Spain
Cabañas V:
Department of Hematology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
Motlló C:
Department of Hematology, Hospital de Sant Joan de Déu, Fundació Althaia, Manresa, Spain
de Cabo E:
Department of Hematology, Hospital de El Bierzo, León, Spain
Encinas C:
Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Murillo I:
Department of Hematology, Hospital General San Jorge, Huesca, Spain
Hernández-Rivas JÁ:
Department of Hematology, Hospital Universitario Infanta Leonor, Madrid, Spain
Pérez-Persona E:
Department of Hematology, Hospital Txagorritxu, Vitoria, Spain
Casado F:
Department of Hematology, Complejo Hospitalario de Toledo, Toledo, Spain
Sampol A:
Department of Hematology, Hospital Universitario Son Espases, Mallorca, Spain
García R:
Department of Hematology, Complejo Hospitalario de Especialidades Virgen de la Victoria, Málaga, Spain
Blanchard MJ:
Department of Hematology, Hospital Ramón Y Cajal, Madrid, Spain
Anguita M:
Department of Hematology, Hospital de Jaén, Jaén, Spain
Lafuente AP:
Department of Hematology, Hospital del Tajo, Madrid, Spain
Iñigo B:
Department of Hematology, Hospital Clínico San Carlos, Madrid, Spain
López A:
Department of Hematology, Hospital Arnau de Vilanova, Lleida, Spain
:
Department of Hematology, Hospital Universitario Dr Peset Aleixandre, Valencia, Spain
Arnao M:
Department of Hematology, Hospital Universitario La Fe, Valencia, Spain
Maldonado R:
Fundación PETHEMA, Madrid, Spain
Bladé J:
Department of Hematology, Hospital Clinic de Barcelona, IDIBAPS, Barcelona, Spain
Mateos MV:
Department of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain
Lahuerta JJ:
Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain
San Miguel JF:
Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain
|